Chronic granulomatous disease ' conventional treatment vs. hematopoietic stem cell transplantation: An update

Current Opinion in Hematology

Volumn 22, Issue 1, 2015, Pages 41-45

  Ahlin, Anders ^a   Fasth, Anders ^b  

^a SACHS CHILDREN S HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Antifungal treatment; Chronic granulomatous disease; Conventional treatment; Hematopoietic stem cell transplantation; Infections; Inflammation; Morbidity; Mortality

Indexed keywords

ANTIFUNGAL AGENT; PYRROLE DERIVATIVE;

BACTERIAL INFECTION; CHRONIC GRANULOMATOUS DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; INFLAMMATORY DISEASE; MORBIDITY; MORTALITY; MYCOSIS; QUALITY OF LIFE; REDUCED INTENSITY CONDITIONING; REVIEW; STEROID THERAPY; SURVIVAL; ALLOGRAFT; GRANULOMATOUS DISEASE, CHRONIC; PATHOLOGY;

ALLOGRAFTS; ANTIFUNGAL AGENTS; AZOLES; GRANULOMATOUS DISEASE, CHRONIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS;

EID: 84916893872     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000097     Document Type: Review

References (33)

1. Leiding JW, Holland SM. Chronic granulomatous disease. In: Pagon RA, Adam MP, Ardinger HH, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K, editors. GeneReviews1 [Internet]. Seattle, WA: University of Washington; 2012. pp. 1993-2014.
2. Kang EM, Malech HL. Gene therapy for chronic granulomatous disease. Methods Enzymol 2012; 507:125-154.
3. Van de Veerdonk FL, Dinarello CA. Deficient autophagy unravels the ROS paradox in chronic granulomatous disease. Autophagy 2014; 6:1141-1142.
4. DeLuca A, Smeekens SP, Casagrande A, et al. IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous diseasein mice and in humans. Proc Natl Acad Sci USA 2014; 111:3526-3531.
5. Magnani A, Brosselin P, Beauté J, et al. Inflammatory manifestations in a single-center cohort of patients with chronic granulomatous disease. J Allergy Clin Immunol 2014; 134:655-662.
6. Rieber N, Hector A, Kuijpers T, et al. Current concepts of hyperinflammation in chronic granulomatous disease. Clin Dev Immunol 2012; 2012:252460.
7. Uzel G, Orange JS, Poliak N, et al. Complications of tumor necrosis factor-a blockade in chronic granulomatous disease-related colitis. Clin Infect Dis 2010; 12:1429-1434.
8. Cole T, Pearce MS, Cant AJ, et al. Clinical outcome in children with chronic granulomatous disease managed conservatively or with hematopoietic stem cell transplantation. J Allergy Clin Immunol 2013; 132:1150-1155.
9. Yamazaki-Nakashimada MA, Stiehm ER, Pietropaolo-Cienfuegos D, et al. Corticosteroid therapy for refractory infections in chronic granulomatous disease: case reports and review of the literature. Ann Allergy Asthma Immunol 2006; 2:257-261.
10. Freeman AF, Marciano BE, Anderson VL, et al. Corticosteroids in the treatment of severe Nocardia pneumonia in chronic granulomatous disease. Pediatr Infect Dis J 2011; 30:806-808.
11. Feld JJ, Hussain N, Wright EC, et al. Hepatic involvement and portal hypertension predict mortality in chronic granulomatous disease. Gastroenterology 2008; 134:1917-1926.
12. Leiding JW, Freeman AF, Marciano BE, et al. Corticosteroid therapy for liver abscess in chronic granulomatous disease. Clin Infect Dis 2012; 54:694-700.
13. Blumental S, Mouy R, Mahlaoui N, et al. Invasive mold infections in chronic granulomatous disease: a 25-year retrospective survey. Clin Infect Dis 2011; 53:e159-e169.
14. Dotis J, Pana ZD, Roilides E. Non-aspergillus fungal infections in chronic granulomatous disease. Mycoses 2013; 56:449-462.
15. Winkelstein JA, Marino MC, Johnston RB Jr, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000; 79:155-169.
16. Van den Berg JM, van Koppen E, Ahlin A, et al. Chronic granulomatous disease: the European experience. PLoS One 2009; 4:e5234.
17. Beauté J, Obenga G, Le Mignot L, et al., French PID Study Group CEREDIH. Epidemiology and outcome of invasive fungal diseases in patients with chronic granulomatous disease: a multicenter study in France. Pediatr Infect Dis J 2011; 30:57-62.
18. Seyedmousavi S, Mouton JW, Melchers WJ, et al. The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside. Drug Resist Updat 2014; 17:37-50.
19. Horwitz ME, Barrett AJ, Brown MR, et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hemato-poietic allograft. N Engl J Med 2001; 344:881-888.
20. Seger RA, Gungor T, Belohradsky BH, et al. Treatment of chronic granuloma-tous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience. Blood 2002; 100:4344-4350.
21. Soncini E, Slatter MA, Jones LB, et al. Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth. Br J Haematol 2009; 145:73-83.
22. Schuetz C, Hoenig M, Gatz S, et al. Hematopoietic stem cell transplantation from matched unrelated donors in chronic granulomatous disease. Immunol Res 2009; 44:35-41.
23. Tewari P, Martin PL, Mendizabal A, et al. Myeloablative transplantation using either cord blood or bone marrow leads to immune recovery, high long-term donor chimerism and excellent survival in chronic granulomatous disease. Biol Blood Marrow Transplant 2012; 18:1368-1377.
24. Martinez CA, Shah S, Shearer WT, et al. Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. J Allergy Clin Immunol 2012; 129:176-183.
25. Ahlin A, Fugeläng J, de Boer M, et al. Chronic granulomatous disease-haematopoietic stem cell transplantation versus conventional treatment. Acta Paediatr 2013; 102:1087-1094.
26. Güngör T, Teira P, Slatter M, et al. Inborn Errors Working Party of the European Society for Blood and Marrow Transplantation. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet 2014; 383:436-448.
27. Cole T, McKendrick F, Titman P, et al. Health related quality of life and emotional health in children with chronic granulomatous disease: a compar ison of those managed conservatively with those that have undergone haematopoietic stem cell transplant. J Clin Immunol 2013; 33:8-13.
28. Cole TS, McKendrick F, Cant AJ, et al. Cognitive ability in children with chronic granulomatous disease: a comparison of those managed conservatively with those who have undergone hematopoietic stem cell transplant. Neuropedia-trics 2013; 44:230-232.
29. Henriet S, Verweij PE, Holland SM, et al. Invasive fungal infections in patients with chronic granulomatous disease. Adv Exp Med Biol 2013; 764:27-55.
30. Martire B, Rondelli R, Soresina A, et al. Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study. Clin Immunol 2008; 126:155-164.
31. Kuhns DB, Alvord WG, Heller T, et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med 2010; 363:2600-2610.
32. Jones LB, McGrogan P, Flood TJ, et al. Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry. Clin Exp Immunol 2008; 2:211-218.
33. EBMT/ESID guidelines for haematopoietic stem cell transplantation for primary immunodeficiencies. http://www.ebmt.org/Contents/Research/The WorkingParties/IEWP/Pages/Inborn-Errors.aspx. [Accessed 4 September 2014]